Strathprints Home | Open Access | Browse | Search | User area | Copyright | Help | Library Home | SUPrimo

Inhibition of in-stent stenosis by oral administration of bindarit in porcine coronary arteries

Ialenti, A. and Grassia, G. and Gordon, P. and Maddaluno, M. and Di Lauro, M. V. and Baker, A. H. and Guglielmotti, A. and Colombo, A. and Biondi, G. and Kennedy, S. and Maffia, Pasquale (2011) Inhibition of in-stent stenosis by oral administration of bindarit in porcine coronary arteries. Arteriosclerosis, Thrombosis, and Vascular Biology, 31 (11). 2448-U230. ISSN 1079-5642

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

We have previously demonstrated that bindarit, a selective inhibitor of monocyte chemotactic proteins (MCPs), is effective in reducing neointimal formation in rodent models of vascular injury by reducing smooth muscle cell proliferation and migration and neointimal macrophage content, effects associated with the inhibition of MCP-1/CCL2 production. The aim of the current study was to evaluate the efficacy of bindarit on in-stent stenosis in the preclinical porcine coronary stent model. One or 2 bare metal stents (Multi-Link Vision, 3.5 mm) were deployed (1: 1.2 oversize ratio) in the coronary arteries of 42 pigs (20 bindarit versus 22 controls). Bindarit (50 mg/kg per day) was administered orally from 2 days before stenting until the time of euthanasia at 7 and 28 days. Bindarit caused a significant reduction in neointimal area (39.4%, P < 0.001, n = 9 group), neointimal thickness (51%, P < 0.001), stenosis area (37%, P < 0.001), and inflammatory score (40%, P < 0.001) compared with control animals, whereas there was no significant difference in the injury score between the 2 groups. Moreover, treatment with bindarit significantly reduced the number of proliferating cells (by 45%, P < 0.05; n = 6 group) and monocyte/macrophage content (by 55%, P < 0.01; n = 5-6 group) in stented arteries at day 7 and 28, respectively. These effects were associated with a significant (P < 0.05) reduction of MCP-1 plasma levels at day 28. In vitro data showed that bindarit (10-300 mu mol/L) reduced tumor necrosis factor-alpha (50 ng/mL)-induced pig coronary artery smooth muscle cell proliferation and inhibited MCP-1 production. Our results show the efficacy of bindarit in the prevention of porcine in-stent stenosis and support further investigation for clinical application of this compound. (Arterioscler Thromb Vasc Biol. 2011;31:2448-2454.)

Item type: Article
ID code: 41580
Keywords: animal-models, hyperplasia, restenosis, bindarit, neointima formation, pharmacology, monocyte chemoattractant protein-1, mcp-1 synthesis, protects mice, antiinflammatory agent bindarit, stent, local-delivery, chemotactic proteins, Pharmacy and materia medica, Cardiology and Cardiovascular Medicine
Subjects: Medicine > Pharmacy and materia medica
Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
Related URLs:
Depositing user: Pure Administrator
Date Deposited: 19 Oct 2012 14:59
Last modified: 27 Mar 2014 10:36
URI: http://strathprints.strath.ac.uk/id/eprint/41580

Actions (login required)

View Item